The global liquid biopsy market was estimated to be at $2,508.2 million in 2021, which is expected to grow with a CAGR of 19.83% and reach $19,066.0 million by 2032. The growth in the global liquid biopsy market is expected to be driven by increasing adoption of NGS in various research fields, advancement in NGS, and increase in the adoption of personalized medicine.
Recent Developments in the Global Liquid Biopsy Market
• Product Launch in 2020: Sysmex Corporation launched liquid biopsy RUO kits in EMEA region. The kits name is Plasma-SeqSensei, and it is used for non-small cell lung cancer (NSCLC), melanoma, and thyroid cancer.
• Partnership: In 2021, Illumina, Inc. collaborated with Bristol Myers Squibb to innovate and enhance companion diagnostics for therapy selection to further precision oncology. TSO 500 ctDNA is one of the first liquid biopsy assays to enable comprehensive genomic profiling for therapy selection.
• Collaboration: In 2021, QIAGEN collaborated with Sysmex Corporation for the development and commercialization of cancer companion diagnostics using NGS and Plasma-Safe-SeqS technology.
Key Questions Answered in the Report
- What are the major market drivers, challenges, and opportunities in the global liquid biopsy market?
- What are the key development strategies which are implemented by the major players to sustain in the competitive market?
- Which is the dominant product type developed by the leading and emerging players for liquid biopsy?
- What are the key technologies that have been used by leading players in the global liquid biopsy market to develop diagnostic and research solutions for cancer?
- How is each segment of the market expected to grow during the forecast period from 2022 to 2032? Following are the segments:Which companies are anticipated to be highly disruptive in the future, and why?
- Offering (testing service, kits, other consumables, and platform)
- Technology (next-generation sequencing (NGS), polymerase chain reaction (PCR), other technologies, and emerging technologies)
- Usage (research and clinical)
- Circulating Biomarker (circulating tumor cells, cell-free DNA, circulating cell-free RNAs, exosomes and extracellular vesicles and others, and other circulating biomarkers)
- Workflow (sample preparation, library preparation, sequencing, and data analysis and management)
- Sample (blood, urine, saliva and others)
- Indication (lung cancer, breast cancer, prostate cancer, colorectal cancer, melanoma, other types of cancer, and non-oncology disorder)
- Clinical Application (treatment monitoring, prognosis and recurrence monitoring, treatment selection and diagnosis and screening)
- End User (academic and research institutions, clinical laboratories, pharmaceutical and biotechnology companies, and other end users)
- Region (North America, Europe, Asia-Pacific, Latin America and Middle East, and Rest-of-the-World)
- What are the reimbursement scenario and the regulations for liquid biopsies globally?
- Considering next-generation sequencing (NGS), what is the most important factor among price, sensitivity, and turnaround time, to increase the adoption of NGS-based liquid biopsy in the near future?
- From the end-users’ point of view, does efficiency or convenience hold the key to driving the global liquid biopsy market?
- What are your treatment guidelines for the different types of cancer?
- What is the average number of liquid biopsies being conducted on each patient throughout the duration of their stay?
Get Free Sample Report - https://bisresearch.com/requestsample?id=1303type=download
|
